BioCentury
ARTICLE | Clinical News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

September 28, 2018 5:25 PM UTC

EMA's CHMP on Sept. 21 recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam.

CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta Therapeutics (NASDAQ:SRPT) for Duchenne muscular dystrophy...